REGULATORY
Up-to-5-Band Plan OK’ed for Unreasonable Generic Price Rises, Change to Affect Single Price Band Rule Too
A key reimbursement policy panel roughly approved a draft outline of next April’s drug pricing reform package on December 13, which included a plan to create separate price bands for both middle and lower bands under the current three price-band…
To read the full story
Related Article
REGULATORY
- Lilly’s Oral GLP-1 Obesity Drug Heads to Dec. 2 Panel Review, Eyes Japan First
November 19, 2026
- First Pralia Biosimilars Inching Closer to Japan Approval, 5 Products Lined Up
November 19, 2026
- MHLW Drug Supply Monitoring System Hit by Cyberattack, Possible Data Leak
November 19, 2026
- Expert Calls for Remote MRI Reviews to Monitor Alzheimer’s Drug Risks
November 18, 2026
- Japan Implements ICH Bioequivalence Guideline for Immediate-Release Oral Drugs
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





